Relief Therapeutics Forms Exclusive Agreement with Eton Pharmaceuticals for PKU GOLIKE in the U.S.

Relief Therapeutics Holding SA, a biopharmaceutical firm, has announced an exclusive licensing and supply agreement with Eton Pharmaceuticals for the commercialization of the PKU GOLIKE product family in the United States. This partnership aligns with Relief's strategy of advancing the GOLIKE products through partnership models in the U.S. and Europe.

Eton Pharmaceuticals, with its experience in the metabolic domain, aims to enhance awareness and adoption of PKU GOLIKE, a product aimed at the estimated $100 million U.S. PKU medical formula market. The agreement involves an upfront payment of $2.2 million to Relief, potential sales milestone payments of up to $2.0 million, and mid-teens royalties on net sales.

Since its U.S. launch in late 2022, PKU GOLIKE has seen a positive growth trajectory. The partnership also grants Eton the U.S. rights to Relief’s GOLIKE Medical Food line extensions for managing other inherited rare metabolic diseases, expected to launch in 2025 and 2026. Additionally, discussions are ongoing regarding other development assets, including the PKU treatment candidate RLF-OD032.